Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease

被引:7
|
作者
Olafsdottir, Arndis Finna [1 ,2 ]
Andelin, Mervi [1 ]
Saeed, Aso [3 ]
Sofizadeh, Sheyda [1 ]
Hamoodi, Hussein [4 ]
Jansson, Per-Anders [5 ]
Lind, Marcus [1 ,2 ]
机构
[1] NU Hosp Grp, Dept Med, Fjallvagen 9, Uddevalla, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden
[3] Gothenburg Univ, Sahlgrenska Acad, Inst Internal Med, Dept Nephrol, Gothenburg, Sweden
[4] Statistiska Konsultgruppen, Gothenburg, Sweden
[5] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Wallenberg Lab,Dept Mol & Clin Med, Gothenburg, Sweden
关键词
Type; 1; diabetes; 2; Chronic kidney disease; Continuous glucose monitoring; Accuracy; Mean absolute relative difference; TREATMENT EXPERIENCE; CLINICAL-TRIAL; GLUCOSE; ACCURACY; SYSTEM;
D O I
10.12998/wjcc.v10.i22.7794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Advanced chronic kidney disease (CKD) is a common complication for people with type 1 and 2 diabetes and can often lead to glucose instability. Continuous glucose monitoring (CGM) helps users monitor and stabilize their glucose levels. To date, CGM and intermittent scanning CGM are only approved for people with diabetes but not for those with advanced CKD. AIM To compare the performance of Dexcom G5 and FreeStyle Libre sensors in adults with type 1 or 2 diabetes and advanced CKD. METHODS This was a non-randomized clinical trial that took place in two outpatient clinics in western Sweden. All patients with type 1 or 2 diabetes and an estimated glomerular filtration rate (eGFR) of < 30 mL/min per 1.73 m(2) were invited to participate. Forty patients (full analysis set = 33) carried the Dexcom G5 sensor for 7 d and FreeStyle Libre sensor for 14 d simultaneously. For referencing capillary blood glucose (SMBG) was measured with a high accuracy glucose meter (HemoCue (R)) during the study period. At the end of the study, all patients were asked to answer a questionnaire on their experience using the sensors. RESULTS The mean age was 64.1 (range 41-77) years, hemoglobin A1c was 7.0% [standard deviation (SD) 3.2], and diabetes duration was 28.5 (SD 14.7) years. A total of 27.5% of the study population was on hemodialysis and 22.5% on peritoneal dialysis. The mean absolute relative difference for Dexcom G5 vs SMBG was significantly lower than that for FreeStyle Libre vs SMBG [15.2% (SD 12.2) vs 20.9% (SD 8.6)], with a mean difference of 5.72 [95% confidence interval (CI): 2.11-9.32; P = 0.0036]. The mean absolute difference was also significantly lower for Dexcom G5 than for FreeStyle Libre, 1.21 mmol/L (SD 0.78) and 1.76 mmol/L (SD 0.78), with a mean diffrenec of 0.55 (95%CI: 0.27-0.83; P = 0.0004).The mean difference (MD) was -0.107 mmol/L and -1.10 mmol/L (P = 0.0002), respectively. In all, 66% of FreeStyle Libre values were in the no risk zone on the surveillance error grid compared to 82% of Dexcom G5 values. CONCLUSION Dexcom G5 produces more accurate sensor values than FreeStyle Libre in people with diabetes and advanced CKD and is likely safe to be used by those with advanced CKD.
引用
收藏
页码:7794 / 7807
页数:14
相关论文
共 50 条
  • [41] Prevalence and characteristics of chronic kidney disease in people with type 2 diabetes mellitus in the Autonomous Community of Aragon
    Sanchez-Calavera, Maria Antonia
    Navarro, Rafael Gomez
    Otal, Elena Asso
    Gonzalez, Isabel Blasco
    Pardo, Daniel Escribano
    Celma, Laia Homedes
    Lamarre, Michelot
    Esteban, Pilar Lopez
    del Hoyo, Maria Luisa Lozano
    Mahulea, Liliana
    Gallego, Ines Mera
    Romero-Vigara, Juan Carlos
    Allue, Sandra Soler
    Hueso, Sira Telmo
    Gil, Fran Adan
    PRIMARY CARE DIABETES, 2024, 18 (05) : 555 - 560
  • [42] Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study
    Jo-Anne Manski-Nankervis
    Sharmala Thuraisingam
    Janet K. Sluggett
    Gary Kilov
    John Furler
    David O’Neal
    Alicia Jenkins
    BMC Family Practice, 20
  • [43] Screening and diagnosis of chronic kidney disease in people with type 2 diabetes attending Australian general practice
    Manski-Nankervis, Jo-Anne E.
    Thuraisingam, Sharmala
    Lau, Phyllis
    Blackberry, Irene
    Sluggett, Janet K.
    Ilomaki, Jenni
    Bell, J. Simon
    Furler, John
    AUSTRALIAN JOURNAL OF PRIMARY HEALTH, 2018, 24 (03) : 280 - 286
  • [44] The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review
    Sloan, Lance
    Cheng, Alice Y. Y.
    Escalada, Javier
    Haluzik, Martin
    Mauricio, Didac
    DIABETES OBESITY & METABOLISM, 2024, 26 (04): : 1157 - 1170
  • [45] GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease
    Koufakis, Theocharis
    Popovic, Djordje S.
    Karakasis, Paschalis
    Georgianos, Panagiotis
    Patoulias, Dimitrios
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (15) : 1979 - 1982
  • [46] Secular trends of chronic kidney disease in people with type 1 and type 2 diabetes in developing countries (2005-2017): the IDMPS study
    Mbanya, J. C.
    Aschner, P.
    Gagliardino, J. J.
    Ilkova, H.
    Lavalle, F.
    Ramachandran, A.
    Shestakova, M.
    Chantelot, J. -M.
    Chan, J. C. N.
    DIABETOLOGIA, 2019, 62 : S489 - S489
  • [47] Secondary hyperparathyroidism and osteopenic syndrome in patients with diabetes type 1 and type 2 and chronic kidney disease
    Alikhanova, N.
    Aykhodjaeva, M. A.
    Nazarova, N. S.
    DIABETOLOGIA, 2016, 59 : S491 - S492
  • [48] Identification of markers for predicting the onset of chronic kidney disease in older people with type 2 diabetes bymetabolomic profiling: Edinburgh Type 2 Diabetes Study
    Krasauskaite, J.
    Conway, B. R.
    Weir, C. J.
    Huang, Z.
    Price, J. F.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S22 - S23
  • [49] Metallothionein MT2A A-5G Polymorphism and the Risk for Chronic Kidney Disease and Diabetes
    Kawada, Tomoyuki
    TOXICOLOGICAL SCIENCES, 2016, 154 (02) : 198 - 198
  • [50] Identification of genetic association of Thyroid Cancer with Parkinsons disease, Osteoporosis, chronic heart failure, Chronic kidney disease, Type 1 diabetes and Type 2 diabetes
    Hossain, Md Ali
    Asa, Tania Akter
    Islam, Sheikh Muhammad Saiful
    Hussain, Muhammad Sajjad
    Moni, Mohammad Ali
    2019 5TH INTERNATIONAL CONFERENCE ON ADVANCES IN ELECTRICAL ENGINEERING (ICAEE), 2019, : 832 - 837